As the industry—and the world—faces unprecedented challenges, your choice of CDMO plays an increasingly important role in the success of your project. New formulations and underserved patient populations demand a level of expertise many development and manufacturing partners simply don’t have. Is your CDMO partner able to adapt to today’s ever-changing world? Giovanni Ortenzi, the leader of Adare Pharma’s global pharmaceutical development and technical services, was recently interviewed about how Adare is uniquely qualified to meet and overcome these new challenges. Adare’s unique mix of expertise, innovation, and capacity makes us the perfect choice to bring your new project to market.
Advanced LC-MS Technology for Enhanced HCP Detection in Complex Biotherapeutics
February 26th 2025The identification, characterization, and quantitation of host cell protein (HCP) impurities are a critical challenge in the biopharmaceutical industry. Advanced LC-MS techniques can be integrated into manufacturing workflows to mitigate risks and ensure higher product quality and improved patient safety.